{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:31:15Z","timestamp":1794483075547,"version":"4.9.1"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In chronic myeloid leukemia, the identification of early molecular predictors of stable treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation is challenging. The predictive values of residual disease (BCR::ABL1 quantification) at month 3 and 6 and more recently, BCR::ABL1 transcript halving time (HT) have been described, but no study compared the predictive value of different early parameters. Using a real-world cohort of 408 patients, we compared the performance of the EUTOS long-term survival (ELTS) score, BCR::ABL1 HT, and residual disease at month 3 and 6 to predict the molecular response, achievement of the TKI discontinuation criteria, and TFR maintenance. The performances of BCR::ABL1 HT and residual disease at month 3 were similar. Residual disease at month 6 displayed the best performance for predicting the optimal response (area under the ROC curve between 0.81 and 0.92; cut-off values: 0.11% for MR4 at month 24 and 0.12% for MR4.5 at month 48). Conversely, no early parameter predicted reaching the TKI discontinuation criteria and TFR maintenance. We obtained similar results when patients were divided in subgroups by first-line treatment (imatinib vs. second-generation TKI [2G-TKI]). We identified a relationship between ELTS score, earlier milestones and TFR maintenance only in the 2G-TKI group. In conclusion, this first comparative study of early therapeutic response parameters showed that they are excellent indicators of TKI efficacy (BCR::ABL1 transcript reduction) and best responders. Conversely, they did not predict the achievement of the TKI discontinuation criteria and TFR maintenance, suggesting that other parameters are involved in TFR maintenance.<\/jats:p>","DOI":"10.3324\/haematol.2023.284860","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T03:58:31Z","timestamp":1714622311000},"page":"2893-2907","source":"Crossref","is-referenced-by-count":10,"title":["The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort"],"prefix":"10.3324","volume":"109","author":[{"given":"Sandrine","family":"Saugues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Roth-Guepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Cony-Makhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyacinthe Johnson","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre-Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u00ef","family":"Tchirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalil","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"65735","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Larson RA, Guilhot F. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10):917-27.","DOI":"10.1056\/NEJMoa1609324"},{"key":"65736","doi-asserted-by":"crossref","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851-2857.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"65737","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Hughes TP, Larson RA. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2):440-453.","DOI":"10.1038\/s41375-020-01111-2"},{"key":"65738","doi-asserted-by":"crossref","unstructured":"Saugues S, Lambert C, Daguenet E. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory. Ann Hematol. 2022; 101(10):2241-2255.","DOI":"10.1007\/s00277-022-04955-z"},{"key":"65739","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019; 9:603.","DOI":"10.3389\/fonc.2019.00603"},{"key":"65740","doi-asserted-by":"crossref","unstructured":"Vener C, Banzi R, Ambrogi F. First-line imatinib vs second-and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020; 4(12):2723-2735.","DOI":"10.1182\/bloodadvances.2019001329"},{"key":"65741","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-884.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"65742","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"65743","doi-asserted-by":"crossref","unstructured":"Baccarani M, Cortes J, Pane F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-6051.","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"65744","doi-asserted-by":"crossref","unstructured":"Marin D, Ibrahim AR, Lucas C. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3):232-238.","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"65745","doi-asserted-by":"crossref","unstructured":"Neelakantan P, Gerrard G, Lucas C. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013; 121(14):2739-2742.","DOI":"10.1182\/blood-2012-11-466037"},{"key":"65746","doi-asserted-by":"crossref","unstructured":"Branford S, Yeung DT, Ross DM. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013; 121(19):3818-3824.","DOI":"10.1182\/blood-2012-10-462291"},{"key":"65747","doi-asserted-by":"crossref","unstructured":"Gerds AT, Gotlib J, Ali H. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(9):1033-1062.","DOI":"10.6004\/jnccn.2022.0046"},{"key":"65748","doi-asserted-by":"crossref","unstructured":"Senapati J, Sasaki K, Issa GC. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023; 13(1):58.","DOI":"10.1038\/s41408-023-00823-9"},{"key":"65749","doi-asserted-by":"crossref","unstructured":"Narl\u0131 \u00d6zdemir Z, K\u0131l\u0131\u00e7aslan NA, Y\u0131lmaz M, E\u015fkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023; 117(1):3-15.","DOI":"10.1007\/s12185-022-03446-1"},{"key":"65750","doi-asserted-by":"crossref","unstructured":"Branford S, Yeung DT, Parker WT. Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014; 124(4):511-518.","DOI":"10.1182\/blood-2014-03-566323"},{"key":"65751","doi-asserted-by":"crossref","unstructured":"Shanmuganathan N, Pagani IS, Ross DM. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021; 137(9):1196-1207.","DOI":"10.1182\/blood.2020005514"},{"key":"65752","doi-asserted-by":"crossref","unstructured":"Iriyama N, Fujisawa S, Yoshida C. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015; 90(4):282-287.","DOI":"10.1002\/ajh.23923"},{"key":"65753","doi-asserted-by":"crossref","unstructured":"Fava C, Rege-Cambrin G, Dogliotti I. Early BCR-ABL1 reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor. Clin Lymphoma Myeloma Leuk. 2016; 16:S96-S100.","DOI":"10.1016\/j.clml.2016.03.008"},{"key":"65754","doi-asserted-by":"crossref","unstructured":"Pennisi MS, Stella S, Vitale SR. BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors. Front Oncol. 2019; 9:764.","DOI":"10.3389\/fonc.2019.00764"},{"key":"65755","doi-asserted-by":"crossref","unstructured":"Cai Z, Jia X, Zi J. BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia. J Cancer. 2020; 11(8):2234-2240.","DOI":"10.7150\/jca.38752"},{"key":"65756","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Baccarani M, Saussele S. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016; 30(1):48-56.","DOI":"10.1038\/leu.2015.261"},{"key":"65757","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"65758","doi-asserted-by":"crossref","unstructured":"Sato E, Iriyama N, Tokuhira M. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020; 9(23):8931-8939.","DOI":"10.1002\/cam4.3516"},{"key":"65759","doi-asserted-by":"crossref","unstructured":"Zhang X-S, Gale RP, Huang X-J, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia. 2022; 36(2):482-491.","DOI":"10.1038\/s41375-021-01387-y"},{"key":"65760","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-845.","DOI":"10.2307\/2531595"},{"key":"65761","doi-asserted-by":"crossref","unstructured":"Liu X. Classification accuracy and cut point selection. Stat Med. 2012; 31(23):2676-2686.","DOI":"10.1002\/sim.4509"},{"key":"65762","doi-asserted-by":"crossref","unstructured":"Feise RJ. Do multiple outcome measures require p-value adjustment?. BMC Med Res Methodol. 2002; 2:8.","DOI":"10.1186\/1471-2288-2-8"},{"key":"65763","doi-asserted-by":"crossref","unstructured":"Cayuela J-M, Chomel J-C, Coiteux V. Recommandations du France Intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC) pour l\u2019examen des mutations du domaine kinase de BCR-ABL1 dans la leuc\u00e9mie my\u00e9lo\u00efde chronique. Bull Cancer. 2020; 107(1):113-128.","DOI":"10.1016\/j.bulcan.2019.05.011"},{"key":"65764","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Shah NP, Hochhaus A. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2260-2270.","DOI":"10.1056\/NEJMoa1002315"},{"key":"65765","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saglio G, Hughes TP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5):1044-1054.","DOI":"10.1038\/leu.2016.5"},{"key":"65766","doi-asserted-by":"crossref","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018; 36(3):231-237.","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"65767","doi-asserted-by":"crossref","unstructured":"Okamoto Y, Hirano M, Morino K. Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response. NPJ Syst Biol Appl. 2022; 8(1):39.","DOI":"10.1038\/s41540-022-00248-3"},{"key":"65768","doi-asserted-by":"crossref","unstructured":"Geelen IGP, Sandin F, Thielen N. Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients. Leukemia. 2018; 32(10):2299-2303.","DOI":"10.1038\/s41375-018-0136-7"},{"key":"65769","doi-asserted-by":"crossref","unstructured":"Hwan Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014; 89(6):626-632.","DOI":"10.1002\/ajh.23707"},{"key":"65770","doi-asserted-by":"crossref","unstructured":"Stella S, Zammit V, Vitale SR. Clinical implications of discordant early molecular responses in CML patients treated with imatinib. Int J Mol Sci. 2019; 20(9):2226.","DOI":"10.3390\/ijms20092226"},{"key":"65771","doi-asserted-by":"crossref","unstructured":"Mikhaeel S, Atallah E. SOHO state of the art updates and next questions\/update on treatment-free remission in chronic myeloid leukemia (CML). Clin Lymphoma Myeloma Leuk. 2023; 23(5):333-339.","DOI":"10.1016\/j.clml.2023.02.008"},{"key":"65772","doi-asserted-by":"crossref","unstructured":"Chen K, Du T, Xiong P, Fan G, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol. 2019; 9:372.","DOI":"10.3389\/fonc.2019.00372"},{"key":"65773","doi-asserted-by":"crossref","unstructured":"Saussele S, Richter J, Guilhot J. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018; 19(6):747-757.","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"65774","doi-asserted-by":"crossref","unstructured":"Dulucq S, Nicolini FE, Rea D. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. Haematologica. 2022; 107(12):2859-2869.","DOI":"10.3324\/haematol.2022.280811"},{"key":"65775","doi-asserted-by":"crossref","unstructured":"Nicolini FE, Dulucq S, Boureau L. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res. 2019; 25(22):6606-6613.","DOI":"10.1158\/1078-0432.CCR-18-3373"},{"key":"65776","doi-asserted-by":"crossref","unstructured":"Atallah E, Schiffer CA, Radich JP. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021; 7(1):42-50.","DOI":"10.1001\/jamaoncol.2020.5774"},{"key":"65777","doi-asserted-by":"crossref","unstructured":"Patterson SD, Copland M. The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities. Curr Hematol Malig Rep. 2023; 18(2):19-32.","DOI":"10.1007\/s11899-023-00688-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284860\/76965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284860\/77429","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11574\/76965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:19Z","timestamp":1794045979000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284860","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}